CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that it ranked No. 2 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing tech companies in North America, now in its 32nd year. ImmunityBio grew over 47,000% during 2022 to 2025.“Ranking No. 2 on the Deloitte Technology Fast 500 list reflects the Company’s significant growth and the expanding adoption of ANKTIVA® in the U.S. and globally,” said